Oral delivery of glucagon-like peptide-1 and analogs: Alternatives for diabetes control?

Journal of Diabetes Science and Technology

Volumn 6, Issue 6, 2012, Pages 1486-1497

  Araújo, Francisca ^a,b   Fonte, Pedro ^a,b   Santos, Hélder A ^c   Sarmento, Bruno ^a,b  

^a Department of Pharmaceutical Sciences Health Sciences Research Center Instituto Superior de Ciências da Saúde ^*  (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Exenatide; Glucagon like peptide 1; Glucagon like peptide 1 analogs; Liraglutide; Oral delivery systems; Type 2 diabetes mellitus

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; NANOPARTICLE; ANTIDIABETIC AGENT; DRUG DERIVATIVE;

ARTICLE; CLINICAL TRIAL (TOPIC); DIABETES CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; HUMAN; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PH; ANIMAL; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84879421792     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600630     Document Type: Article

References (102)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14.
2. Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther. 2010;125(2):328-61.
3. Nicholson G, Hall GM. Diabetes mellitus: new drugs for a new epidemic. Br J Anaesth. 2011;107(1):65-73.
4. Arulmozhi DK, Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci. 2006;28(1-2):96-108.
5. Sadrzadeh N, Glembourtt MJ, Stevenson CL. Peptide drug delivery strategies for the treatment of diabetes. J Pharm Sci. 2007;96(8):1925-54. (Pubitemid 47280092)
6. Marre M, Penfornis A. GLP-1 receptor agonists today. Diabetes Res Clin Pract. 2011;93(3):317-27.
7. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54(1):10-8.
8. Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57. (Pubitemid 46711096)
9. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-39. (Pubitemid 350041474)
10. Steinert RE, Poller B, Castelli MC, Friedman K, Huber AR, Drewe J, Beglinger C. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther. 2009;86(6):644-50.
11. Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr. 2010;92(4):810-7.
12. Takei I, Kasatani T. Future therapy of diabetes mellitus. Biomed Pharmacother. 2004;58(10):578-81. (Pubitemid 40260380)
13. Portha B, Tourrel-Cuzin C, Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res. 2011;2011:376509.
14. Holst JJ, Christensen M, Lund A, de Heer J, Svendsen B, Kielgast U, Knop FK. Regulation of glucagon secretion by incretins. Diabetes Obes Metab. 2011;13 Suppl 1:89-94.
15. Ahrén B. GLP-1 for type 2 diabetes. Exp Cell Res. 2011;317(9):1239-45.
16. Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol. 2000;143(6):717-25. (Pubitemid 32066697)
17. Gallwitz B. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud. 2005;2(2):61-9.
18. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276(5 Pt 2):R1541-4. (Pubitemid 29249681)
19. Neumiller JJ. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther. 2011;33(5):528-76.
20. Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol. 2011;108(3 Suppl):33B-41B.
21. Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care. 2011;34 Suppl 2:S264-71.
22. Vilsboll T, Krarup T, Madsbad S, Holst JJ. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med. 2001;18(2):144-9. (Pubitemid 32238961)
23. Holst JJ, Deacon C, Toft-Nielsen MB, Bjerre-Knudsen L. On the treatment of diabetes mellitus with glucagon-like peptide-1. Ann N Y Acad Sci. 1998;865:336-43. (Pubitemid 29047842)
24. Unger J. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm. J Am Osteopath Assoc. 2011;111(2 Suppl 1):eS2-9.
25. Unger JR, Parkin CG. Glucagon-like peptide-1 (GLP-1) receptor agonists: differentiating the new medications. Diabetes Ther. 2011;2(1):29-39.
26. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34 Suppl 2:S279-84.
27. Li Y, Zheng X, Tang L, Xu W, Gong M. GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1. Peptides. 2011;32(6):1303-12.
28. Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag. 2009;5(1):199-211.
29. Kalra S, Kalra B, Kumar A. GLP-1 analogs: newer molecules, newer uses. Recent Pat Endocr Metab Immune Drug Discov. 2009;3(2):129-34.
30. Chen MC, Sonaje K, Chen KJ, Sung HW. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials. 2011;32(36):9826-38.
31. Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I, Drewe J. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther. 2008;84(4):468-74.
32. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res. 2006;23(8):1675-86. (Pubitemid 44200529)
33. Hamman JH, Demana PH, Olivier EI. Targeting receptors, transporters and site of absorption to improve oral drug delivery. Drug Target Insights. 2007;2:71-81.
34. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20(2-3):153-214. (Pubitemid 37237279)
35. Le Ferrec E, Chesne C, Artusson P, Brayden D, Fabre G, Gires P, Guillou F, Rousset M, Rubas W, Scarino ML. In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods. Altern Lab Anim. 2001;29(6):649-68. (Pubitemid 33126463)
36. Krol S, Ellis-Behnke R, Marchetti P. Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments. Maturitas. 2012;73(1):61-7.
37. Thompson C, Ibie C. The oral delivery of proteins using interpolymer polyelectrolyte complexes. Ther Deliv. 2011;2(12):1611-31.
38. Lee HJ. Protein drug oral delivery: the recent progress. Arch Pharm Res. 2002;25(5):572-84. (Pubitemid 43104176)
39. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158-71.
40. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2011;64(6):557-70.
41. Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol. 2001;280(5):G922-9.
42. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4659-65.
43. Jin Y, Song Y, Zhu X, Zhou D, Chen C, Zhang Z, Huang Y. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials. 2012;33(5):1573-82.
44. Des Rieux A, Fievez V, Theate I, Mast J, Preat V, Schneider YJ. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur J Pharm Sci. 2007;30(5):380-91. (Pubitemid 46436454)
45. Des Rieux A, Fievez V, Momtaz M, Detrembleur C, Alonso-Sande M, Van Gelder J, Cauvin A, Schneider YJ, Préat V. Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. J Control Release. 2007;118(3):294-302. (Pubitemid 46442879)
46. Fearn RA, Hirst BH. Predicting oral drug absorption and hepatobiliary clearance: human intestinal and hepatic in vitro cell models. Environ Toxicol Pharmacol. 2006;21(2):168-78. (Pubitemid 43163090)
47. Griffin BT, O'Driscoll CM. Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther Deliv. 2011;2(12):1633-53.
48. Youn YS, Chae SY, Lee S, Kwon MJ, Shin HJ, Lee KC. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. Eur J Pharm Biopharm. 2008;68(3):667-75. (Pubitemid 351318199)
49. Salamat-Miller N, Johnston TP. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm. 2005;294(1-2):201-16. (Pubitemid 40462336)
50. Qiu Y, Chen Y, Zhang GG, Liu L, Porter WR, eds. Developing solid oral dosage forms: pharmaceutical theory and practice. Burlington: Academic Press; 2009.
51. Assimakopoulos SF, Papageorgiou I, Charonis A. Enterocytes' tight junctions: From molecules to diseases. World J Gastrointest Pathophysiol. 2011;2(6):123-37.
52. Khafagy el-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev. 2007;59(15):1521-46.
53. Park K, Kwon IC, Park K. Oral protein delivery: current status and future prospect. React Funct Polym. 2011;71(3):280-7.
54. Maher S, Brayden DJ. Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discov Today. 2012;9(2):e113-9.
55. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006;11(19-20):905-10. (Pubitemid 44403178)
56. Fonte P, Andrade F, Araujo F, Andrade C, Neves JD, Sarmento B. Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol. 2012;508:295-314.
57. Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta. 2009;1788(4):892-910.
58. Cano-Cebrian MJ, Zornoza T, Granero L, Polache A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv. 2005;2(1):9-22. (Pubitemid 40590917)
59. Liang JF, Yang VC. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun. 2005;335(3):734-8. (Pubitemid 41188260)
60. Chalasani KB, Russell-Jones GJ, Jain AK, Diwan PV, Jain SK. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release. 2007;122(2):141-50. (Pubitemid 47361403)
61. Francis MF, Cristea M, Winnik FM. Exploiting the vitamin B12 pathway to enhance oral drug delivery via polymeric micelles. Biomacromolecules. 2005;6(5):2462-7. (Pubitemid 41388255)
62. Kim SK, Lee EH, Vaishali B, Lee S, Lee YK, Kim CY, Moon HT, Byun Y. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. J Control Release. 2005;105(1-2):32-42. (Pubitemid 40805473)
63. Said HM. Intestinal absorption of water-soluble vitamins in health and disease. Biochem J. 2011;437(3):357-72.
64. Reidling JC, Nabokina SM, Said HM. Molecular mechanisms involved in the adaptive regulation of human intestinal biotin uptake: A study of the hSMVT system. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):G275-81. (Pubitemid 46090270)
65. Ramanathan S, Pooyan S, Stein S, Prasad PD, Wang J, Leibowitz MJ, Ganapathy V, Sinko PJ. Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide. Pharm Res. 2001;18(7):950-6. (Pubitemid 32799939)
66. Said HM. Cell and molecular aspects of human intestinal biotin absorption. J Nutr. 2009;139(1):158-62.
67. Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J Control Release. 2009;133(3):172-7.
68. Lee S, Youn YS, Lee SH, Byun Y, Lee KC. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia. 2006;49(7):1608-11. (Pubitemid 43848097)
69. Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, Lee KC. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem. 2005;16(2):377-82. (Pubitemid 40388214)
70. Youn YS, Chae SY, Lee S, Jeon JE, Shin HG, Lee KC. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol. 2007;73(1):84-93. (Pubitemid 44853930)
71. Youn YS, Jeon JE, Chae SY, Lee S, Lee KC. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice. Diabetes Obes Metab. 2008;10(4):343-6. (Pubitemid 351386031)
72. Chae SY, Chun YG, Lee S, Jin CH, Lee ES, Lee KC, Youn YS. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. J Pharm Sci. 2009;98(4):1556-67.
73. Chae SY, Jin CH, Shin HJ, Youn YS, Lee S, Lee KC. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjug Chem. 2008;19(1):334-41. (Pubitemid 351213867)
74. Hanato J, Kuriyama K, Mizumoto T, Debari K, Hatanaka J, Onoue S, Yamada S. Liposomal formulations of glucagon-like peptide-1: Improved bioavailability and anti-diabetic effect. Int J Pharm. 2009;382(1-2):111-6.
75. Gao Z, Tang Y, Chen J, Bai R, Zhang Q, Hou Y, Lu Y, Bai G. A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres. Peptides. 2009;30(10):1874-81.
76. Kwak HH, Shim WS, Son MK, Kim YJ, Kim TH, Youn HJ, Kang SH, Shim CK. Efficacy of a new sustained-release microsphere formulation of exenatide, DA-3091, in Zucker diabetic fatty (ZDF) rats. Eur J Pharm Sci. 2010;40(2):103-9.
77. Choi S, Baudys M, Kim SW. Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats. Pharm Res. 2004;21(5):827-31. (Pubitemid 39011307)
78. Yin D, Lu Y, Zhang H, Zhang G, Zou H, Sun D, Zhong Y. Preparation of glucagon-like peptide-1 loaded PLGA microspheres: characterizations, release studies and bioactivities in vitro/in vivo. Chem Pharm Bull (Tokyo). 2008;56(2):156-61. (Pubitemid 351206637)
79. Joseph JW, Kalitsky J, St-Pierre S, Brubaker PL. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia. 2000;43(10):1319-28.
80. Cai G, Jiang H. pH-sensitive nanoparticles self-assembled from a novel class of biodegradable amphiphilic copolymers based on chitosan. J Mater Sci Mater Med. 2009;20(6):1315-20.
81. Sonaje K, Lin KJ, Wang JJ, Mi FL, Chen CT, Juang JH, Sung HW. Self-assembled pH-sensitive nanoparticles: a platform for oral delivery of protein drugs. Adv Funct Mater. 2010;20(21):3695-700.
82. Makhlof A, Tozuka Y, Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci. 2011;42(5):445-51.
83. Soga O, van Nostrum CF, Ramzi A, Visser T, Soulimani F, Frederik PM, Bomans PH, Hennink WE. Physicochemical characterization of degradable thermosensitive polymeric micelles. Langmuir. 2004;20(21):9388-95.
84. Sung HW, Sonaje K, Liao ZX, Hsu LW, Chuang EY. pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications. Acc Chem Res. 2012;45(4):619-29.
85. He P, Tang Z, Lin L, Deng M, Pang X, Zhuang X, Chen X. Novel biodegradable and pH-sensitive poly(ester amide) microspheres for oral insulin delivery. Macromol Biosci. 2012;12(4):547-56.
86. Wang XQ, Dai JD, Chen Z, Zhang T, Xia GM, Nagai T, Zhang Q. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J Control Release. 2004;97(3):421-9. (Pubitemid 38802944)
87. Chellampillai B, Pawar AP. Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles. Eur J Drug Metab Pharmacokinet. 2011;35(3-4):123-9.
88. Nguyen HN, Wey SP, Juang JH, Sonaje K, Ho YC, Chuang EY, Hsu CW, Yen TC, Lin KJ, Sung HW. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials. 2011;32(10):2673-82.
89. Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G, Zhang R, Zhang S, Lin L, Chen K, Xie X, Nan F, Young AA, Wang MW. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci U S A. 2007;104(3):943-8. (Pubitemid 46154716)
90. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, Holst JJ, Jeppesen CB, Johnson MD, de Jong JC, Jorgensen AS, Kercher T, Kostrowicki J, Madsen P, Olesen PH, Petersen JS, Poulsen F, Sidelmann UG, Sturis J, Truesdale L, May J, Lau J. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A. 2007;104(3):937-42. (Pubitemid 46154715)
91. Li Y, Xu W, Tang L, Gong M, Zhang J. A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo. Peptides. 2011;32(7):1408-14.
92. Teng M, Johnson MD, Thomas C, Kiel D, Lakis JN, Kercher T, Aytes S, Kostrowicki J, Bhumralkar D, Truesdale L, May J, Sidelman U, Kodra JT, Jørgensen AS, Olesen PH, de Jong JC, Madsen P, Behrens C, Pettersson I, Knudsen LB, Holst JJ, Lau J. Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg Med Chem Lett. 2007;17(19):5472-8. (Pubitemid 47391264)
93. Eldor R, Kidron M, Greenberg-Shushlav Y, Arbit E. Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models. J Diabetes Sci Technol. 2010;4(6):1516-23.
94. Emisphere. www.emisphere.com.
95. Merrion. www.merrionpharma.com.
96. Oramed. www.oramed.com.
97. Novo Nordisk. www.novonordisk.com.
98. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv. 2005;2(2):191-7. (Pubitemid 40488628)
99. Hoffman A, Qadri B. Eligen insulin - a system for the oral delivery of insulin for diabetes. IDrugs. 2008;11(6):433-41. (Pubitemid 351769410)
100. Diabetes in Control. www.diabetesincontrol. com.
101. Leonard TW, Lynch J, McKenna MJ, Brayden DJ. Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin Drug Deliv. 2006;3(5):685-92. (Pubitemid 44383494)
102. Poxel. www.poxel.com.